Regeneron Pharmaceuticals’ attempts to extend the dosing interval for its eye drug, Eylea HD (aflibercept) injection 8mg, have hit a setback, but not one that is likely to hamper the product’s sales to any great extent. More rests on further approval decisions to come as the company hopes to stave off biosimilar competition and that from Roche’s newer rival, Vabysmo.
The US Food and Drug Administration rejected the company’s proposal to add additional extended dosing intervals of up to every...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?